Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Patients who meet ALL the following criteria can be enrolled:~* Male or female aged at least 18 years.~* With a diagnosis of moderate-to-severe chronic plaque psoriasis. As per Belgian National Institute for Health and Disability Insurance (NIHDI), moderate-to-severe plaque psoriasis in adult patients is defined by a Body Surface Area (BSA) \> 10% or aPsoriasis Area and Severity Index (PASI) \> 10.~* For whom the treating dermatologist has made the decision to commence apremilast treatment in accordance with the local label and reimbursement criteria~* Able to follow the instructions of the study.~* Having signed an Informed Consent Form (ICF)~Exclusion Criteria:~Patients who meet AT LEAST one of the following exclusion criteria will be excluded:~* Patients who have received apremilast \> 4 weeks prior to the enrolment visit.~* Women who are pregnant, breastfeeding or planning on becoming pregnant.~* Non-menopausal women who are not using an adequate contraception method.~* Patients with hypersensitivity to apremilast or to one of its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Use of Apremilast in patient with plaque psoriasis (Type: None): Psoriasis patients treated with Otezla® (Apremilast) in Belgium

Based on this trial design, predict the completion outcome and termination type (if applicable).